Literature DB >> 9845256

Resource costing for multinational neurologic clinical trials: methods and results.

K Schulman1, J Burke, M Drummond, L Davies, P Carlsson, J Gruger, A Harris, C Lucioni, R Gisbert, T Llana, E Tom, B Bloom, R Willke, H Glick.   

Abstract

We present the results of a multinational resource costing study for a prospective economic evaluation of a new medical technology for treatment of subarachnoid hemorrhage within a clinical trial. The study describes a framework for the collection and analysis of international resource cost data that can contribute to a consistent and accurate intercountry estimation of cost. Of the 15 countries that participated in the clinical trial, we collected cost information in the following seven: Australia, France, Germany, the UK, Italy, Spain, and Sweden. The collection of cost data in these countries was structured through the use of worksheets to provide accurate and efficient cost reporting. We converted total average costs to average variable costs and then aggregated the data to develop study unit costs. When unit costs were unavailable, we developed an index table, based on a market-basket approach, to estimate unit costs. To estimate the cost of a given procedure, the market-basket estimation process required that cost information be available for at least one country. When cost information was unavailable in all countries for a given procedure, we estimated costs using a method based on physician-work and practice-expense resource-based relative value units. Finally, we converted study unit costs to a common currency using purchasing power parity measures. Through this costing exercise we developed a set of unit costs for patient services and per diem hospital services. We conclude by discussing the implications of our costing exercise and suggest guidelines to facilitate more effective multinational costing exercises.

Entities:  

Mesh:

Year:  1998        PMID: 9845256     DOI: 10.1002/(sici)1099-1050(1998110)7:7<629::aid-hec378>3.0.co;2-n

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  22 in total

Review 1.  Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.

Authors:  C Chevat; B M Peña; M J Al; F F Rutten
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Pharmaceutical care programmes for the elderly: economic issues.

Authors:  Grainne E Crealey; Ian K Sturgess; James C McElnay; Carmel M Hughes
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 6.  Evidence from cost-effectiveness research.

Authors:  Katia Noyes; Robert G Holloway
Journal:  NeuroRx       Date:  2004-07

7.  Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges.

Authors:  Raymond Oppong; Joanna Coast; Kerry Hood; Jacqui Nuttall; Richard D Smith; Christopher C Butler
Journal:  Eur J Health Econ       Date:  2010-04-03

8.  Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference?

Authors:  R Goeree; A Gafni; M Hannah; T Myhr; G Blackhouse
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

9.  Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.

Authors:  G Torrance; V Walker; R Grossman; J Mukherjee; D Vaughan; J La Forge; N Lampron
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

10.  Costing and cost analysis in randomized controlled trials: caveat emptor.

Authors:  Daniel Polsky; Henry Glick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.